Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Graft vs Host Disease 3Neoplasms 2Myelodysplastic Syndromes 2Leukemia 2Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid 1Leukemia, Lymphoid 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hemoglobinopathies 1Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

tofacitinib 6ibrutinib 6Imatinib Mesylate 5ofatumumab 4Rituximab 4nilotinib 3ruxolitinib 2bosutinib 2asciminib 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Dasatinib 2ziconotide 1sodium luminolate 1posaconazole 1pegfilgrastim 1oblimersen 1obinutuzumab 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1fenebrutinib 1canakinumab 1baricitinib 1abexinostat 1Voriconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bronchiolitis Obliterans Syndrome × Photopheresis × Clear all
NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡